Pharma major Glenmark says the operating environment is challenging given the slowdown in India and longer time taken by the US drug regulator for product approvals. It is expecting a 20 percent revenue growth in FY14.
first published: May 8, 2013 11:14 am
A collection of the most-viewed Moneycontrol videos.
Nifty Sees Triple-Digit Cut Despite Strong Q2 From SBI & M&M; All Sectors In Red | Closing Bell Live
Groww's Rs 6,632 Cr IPO Opens For Subscription | Management On Future Path | IPO Watch Live
Realty, PSU Banks Lead Nifty Back Near 25,800; Shriram Finance Scales Record High| Closing Bell Live
Will D-Street See A Sweet Start To November? Autos In Focus After Record Sales| Opening Bell Live
